NCT05023655 2026-03-17Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A MutationPrisma Health-UpstatePhase 2 Terminated20 enrolled
NCT04624113 2024-02-21Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaWashington University School of MedicinePhase 1 Terminated13 enrolled